BioGeneration Ventures — Full Portfolio

Avidicure develops "Actibody", a triple-agonistic antibody platform built on a human IgG scaffold designed to activate the innate and adaptive immune system for treating oncology and autoimmune diseases.

AI & Machine LearningBiotech

Co-investorsEQT Life SciencesBOMCurie CapitalKurma PartnersV-Bio Ventures

i2020 Accelerator (T123 LLC) is a drug discovery accelerator that de-risks early-stage science and advances drug discovery platforms toward lead and clinical candidate stage within roughly two years, working across therapeutic areas such as oncology, immunology, and infectious diseases.

BiotechDeep TechHealthtech

Co-investorsTorrey Pines InvestmentOrbiMed

RhyGaze develops gene therapies using optogenetic proteins to restore sight in patients with vision loss caused by retinal photoreceptor dysfunction.

BiotechDigital HealthMedical DevicesBasel, CH

Botond Roska(Researcher (M.D., Ph.D.))Bence György(IOB Assistant Professor & Head of Clinical Translation)Katherine High(CEO)

Co-investorsARCH Venture PartnersNovartis Venture FundF-Prime CapitalGV (Google Ventures)

Seattle, US

Meininger David(Executive Officer, Director, Promoter)

BoardRoger Ulrich(Director)Daniel O'Connell(Director)

Board seatEdward van Wezel· per SEC Form D · $17.3M raise · filed Apr 2021

Azafaros is a clinical-stage biopharmaceutical company developing nizubaglustat, an orally available azasugar with a dual mode of action targeting the central nervous system and glycosphingolipid metabolism.

BiotechMedical Devices

Co-investorsBioMedPartnersForbionJeito CapitalSeroba Life Sciences

CatalYm develops immunotherapies for solid tumors by neutralizing GDF-15, a protein it identified as a cancer therapy resistance mechanism, aiming to restore anti-tumor immune activity and improve responses to checkpoint inhibitors.

BiotechHealthtech

Co-investorsBayern KapitalCanaan PartnersJeito CapitalNovartis Venture FundBioqube Ventures

Citryll is a biotech company developing CIT-013, a first-in-class monoclonal antibody that targets Extracellular Traps (ETs) to treat immune-mediated inflammatory diseases, with a focus on rheumatoid arthritis and hidradenitis suppurativa.

BiotechHealthtechMedical DevicesOss, NL

Co-investorsBOMCurie CapitalNovartis Venture FundPureos BioventuresForbion

Complement Therapeutics is a clinical-stage biotechnology company developing gene therapies for complement-mediated diseases, with a lead AAV-based candidate (CTx001) for Geographic Atrophy secondary to Age-related Macular Degeneration.

BiotechDigital HealthHealthtechMedical DevicesMunich, DE

Rafiq Hasan(CEO and Managing Director)inMuhammad Ali Memon(Chief Medical Officer)in

Co-investorsHadean VenturesSeroba Life SciencesCambridge Innovation Capital

Co-investorsCapricorn Venture PartnersFund+PMVQuest for GrowthV-Bio Ventures

Cristal Therapeutics develops a proprietary copper-free click chemistry platform, CliCr®, used to create bioconjugate products with higher stability and faster reaction rates.

BiotechDeep Tech

Co-investorsBOMDroia VenturesThuja Capital

Co-investorsEpidarex Capital

Epsilogen develops antibody therapeutics based on the IgE, IgA, and IgG immunoglobulin isotypes for the treatment of cancer, matching each isotype to specific tumor types and combining isotypes into single antibody molecules.

BiotechHealthtech

Tim Wilson(Chief Executive Officer)Kevin FitzGerald(Chief Scientific Officer)Cristina Oliva(Chief Medical Officer)Nick Robbins-Cherry(Chief Financial Officer)Elizabeth Hardaker(Chief Translational Science Officer)

Co-investors3B Future Health FundAlbionVCEpidarex CapitalGlobal BioAccess FundNovartis Venture FundUCL Technology Fund

FundaMental Pharma is a neuroscience drug discovery company developing dual-acting NMDA receptor modulators for treatment-resistant depression.

BiotechDigital Health

The National Kidney Foundation is a nonprofit organization focused on kidney disease, providing patient education, emotional support, and resources for patients, families, living donors, and transplant recipients.

HealthtechImpact & Social Good

Co-investorsYsios CapitalEpidarex CapitalRoche Venture FundScottish National Investment BankSofinnova Partners

Kivu Bioscience is a biotechnology company developing next-generation antibody-drug conjugates (ADCs) for oncology, using site-specific conjugation technology to create more stable and homogeneous cancer therapies with reduced off-tumor toxicity.

BiotechDeep TechHealthtech

Mohit Trikha(CEO)

Co-investorsBOMHealthCapM VenturesRed Tree VentureNovo Holdings

Mellon Medical develops suturing tools for medical specialists, aiming to improve patient outcomes and reduce healthcare costs.

HealthtechMedical Devices

Co-investorsBOMThuja Capital

Mironid is a drug development company building a pipeline of therapies targeting cAMP-degrading phosphodiesterase enzymes to treat Autosomal Dominant Polycystic Kidney Disease (ADPKD) and other rare kidney diseases.

BiotechMedical Devices

Adele Rowley(Chief Scientific Officer)

Co-investorsEpidarex CapitalRoche Venture FundSofinnova PartnersScottish National Investment Bank

River Biomedics develops human cardiac in vitro models used for drug target and compound validation, building a pipeline of cardiac therapies.

BiotechHealthtechMedical Devices

Co-investorsKIKK Capital

Scenic Biotech develops disease-modifying therapies for patients with neurological and metabolic genetic disorders using its Cell-Seq discovery platform to identify modifier genes.

BiotechDeep TechHealthtech

Co-investorsBioMedPartnersEIR VenturesOxford Science EnterprisesInkef

STANT b.v. develops small-molecule STING pathway antagonists with a differentiated mechanism of action, targeting autoimmune, inflammatory, cardiovascular, metabolic and neurodegenerative diseases such as systemic lupus erythematosus, ALS, Parkinson's and chronic kidney disease.

BiotechDeep TechHealthtechOss, NL

Søren R. PaludanSonia Assil

Synaffix develops antibody-drug conjugate (ADC) technology, providing linker-payload platforms that attach small-molecule, peptide, and protein-based payloads to antibodies for use in targeted cancer therapies.

BiotechDeep TechHealthtech

Co-investorsBOMM Ventures

TargED Biopharmaceuticals is a Netherlands-based biotechnology company developing first-in-class biological drugs that use small antibodies (VHH) to deliver enzymes to sites of thrombosis for targeted thrombolysis.

BiotechMedical Devices

Co-investorsAndera PartnersCurie CapitalFund+Hadean VenturesRotripInkef+1 more

Tigatx develops engineered IgA antibodies designed to engage neutrophils as a cancer treatment approach.

Biotech

Co-investorsCivilization Ventures Management, Llc

VarmX is developing VMX-C001, a universal bypassing agent designed to restore blood coagulation in patients taking Factor Xa Direct Oral Anticoagulants (FXa-DOACs).

BiotechMedical Devices

Co-investorsSound BioventuresUNIIQYsios CapitalBGVEICEQT Life Sciences+2 more

XS Innovations is developing a patented implantable valve (XSGuard) that opens the arteriovenous fistula only during dialysis sessions, aiming to control high, turbulent blood flow and reduce vascular access complications.

BiotechMedical Devices